Products ME-401
ME-401 Phase 1 Completed 💤 Quiet Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Apr 29, 2019 → Jan 15, 2025
About ME-401 ME-401 is a phase 1 stage product being developed by Kyowa Kirin for Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03985189. Target conditions include Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma.
Clinical Trials (2) NCT ID Phase Status Start Completion Indication NCT04533581 Phase 2 Active Sep 17, 2020 May 31, 2028 Indolent B-cell Non-Hodgkin's Lymphoma NCT03985189 Phase 1 Completed Apr 29, 2019 Jan 15, 2025 Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Competing Products 20 competing products in Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
See all competitors Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 VIP152 + BTKi Vincerx Pharma Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 AC220 Daiichi Sankyo Phase 1 Valemetostat Tosylate Daiichi Sankyo Phase 2 Linsitinib Astellas Pharma Phase 2 AGS67E Astellas Pharma Phase 1 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib Eisai Phase 2 Tazemetostat Eisai Phase 2 Tazemetostat Eisai Phase 1 Eribulin mesylate Eisai Phase 2 KK2845_1 + KK2845_2 + KK2845_3 + KK2845_4 + KK2845_5 + KK2845_6 Kyowa Kirin Phase 1 Mogamulizumab Kyowa Kirin Phase 2 ONO-4685 Ono Pharmaceutical Phase 1 ONO-4685 Ono Pharmaceutical Phase 1 Tirabrutinib + Rituximab + Temozolomide Ono Pharmaceutical Phase 3 Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + Epcoritamab Eli Lilly Phase 1/2
Other Products from Kyowa Kirin